Clascoterone for Hair Loss: The First New Drug Mechanism in 30 Years

The last time the FDA approved a new drug mechanism for androgenetic alopecia, Bill Clinton was president. Finasteride arrived in 1997. In the nearly three decades since, every approved treatment has worked through the same two pathways: blocking DHT (finasteride, dutasteride) or stimulating blood flow to follicles (minoxidil).

Clascoterone is about to break that streak. Developed by Cosmo Pharmaceuticals (Ireland), it's a topical androgen receptor inhibitor — a cream that blocks DHT at the hair follicle without entering systemic circulation. The same active ingredient is already FDA-approved as Winlevi (1% cream) for acne. The hair loss formulation uses a higher concentration applied directly to the scalp.

On December 3, 2025, Cosmo announced Phase III results across two large clinical trials. The numbers turned heads across dermatology.

The Phase III Results: What the Trials Showed

Cosmo ran two identically designed, randomized, double-blind, vehicle-controlled trials — designated SCALP-1 and SCALP-2 — enrolling a combined 1,465 male patients across the United States and Europe.

The headline number — 539% relative improvement in SCALP-1 — deserves immediate context. That's a relative improvement over the vehicle group, not a 539% increase in total hair count. The absolute hair count changes (the raw number of hairs gained per square centimeter) have not yet been published as of March 2026 and are expected in the peer-reviewed publication later this year.

How Clascoterone Works (and Why It's Different)

Finasteride works by blocking the enzyme (5-alpha-reductase) that converts testosterone into DHT throughout your body. That's why it can cause systemic side effects: it reduces DHT levels everywhere, including in the brain and reproductive system.

Clascoterone takes a fundamentally different approach. Instead of reducing how much DHT your body produces, it blocks DHT from binding to androgen receptors at the follicle itself. It competes with DHT for the receptor — occupying the spot so DHT can't activate the signaling cascade that causes follicle miniaturization.

Because it's applied topically and designed not to absorb systemically, clascoterone shouldn't cause the sexual side effects (reduced libido, erectile changes) that make some men hesitant about finasteride. In the Phase III trials, the safety profile was comparable to the placebo vehicle with no systemic androgen effects detected.

Timeline: When Could Clascoterone Be Available?

That's a best-case timeline. Regulatory submissions can be delayed, the FDA can request additional data, and manufacturing scale-up adds its own timeline. A realistic window for availability is late 2027 through 2028.

What Clascoterone Could Mean for Existing Treatment

For Men Who Can't Tolerate Finasteride

This is potentially the biggest impact. Some men experience side effects on finasteride (or are unwilling to accept the risk). Currently, their primary alternative is minoxidil — which works through a completely different mechanism and doesn't address DHT at all. Clascoterone would offer DHT-blocking efficacy without systemic DHT reduction.

As Combination Therapy

Since clascoterone and finasteride work through different mechanisms, there's theoretical potential for combining them — finasteride reducing systemic DHT production while clascoterone blocks any remaining DHT from reaching the follicle. No combination data exists yet, but this is a logical area for future research.

For Women

Finasteride is generally not prescribed to premenopausal women due to the risk of birth defects. A topical anti-androgen with minimal systemic absorption could be relevant to women's hair loss treatment — though the Phase III trials enrolled only male patients, so female-specific data will be needed.

Frequently Asked Questions

Is clascoterone the same as Winlevi?

Same active ingredient (clascoterone), different formulation and concentration. Winlevi is a 1% cream FDA-approved for acne. The hair loss version uses a higher concentration applied to the scalp. They are not interchangeable — do not use Winlevi on your scalp expecting hair growth results.

Will clascoterone replace finasteride?

Probably not for everyone. Finasteride has nearly 30 years of long-term safety and efficacy data. It costs as little as $3–5/month generic. Even if clascoterone proves comparably effective, it will likely be significantly more expensive at launch and will take years to build a comparable long-term evidence base. It's more likely to become an alternative for men who can't tolerate finasteride, or an addition to existing regimens.

Should I stop my current treatment while waiting?

Absolutely not. If you stop finasteride or minoxidil while waiting for clascoterone, you'll lose the ground you've gained. Any hair maintained by current medications will thin or fall out within months of stopping. Start or continue proven treatments now. You can always add clascoterone to your regimen if and when it becomes available.

The Bottom Line

Clascoterone represents the most significant advance in hair loss pharmacology since finasteride was approved in 1997. The Phase III results are genuinely encouraging — 1,465 patients, statistically significant improvement, and a safety profile comparable to placebo.

But we need to see the absolute hair count data, understand the discrepancy between the two trial results, and wait for the full peer-reviewed publication. Regulatory approval is realistically 18–24 months away. In the meantime, finasteride, minoxidil, and combination therapy remain proven, available, and effective for the majority of men with androgenetic alopecia.

For the full picture of what else is in development, see our 2026 drug pipeline tracker.